Wang J, Zhuang P, Lin B, Zheng J, Li H, Tang W
Front Microbiol. 2025; 15:1503302.
PMID: 39764447
PMC: 11701008.
DOI: 10.3389/fmicb.2024.1503302.
Goodrich J, Wang H, Jia Q, Stratakis N, Zhao Y, Maitre L
Environ Int. 2024; 190:108930.
PMID: 39128376
PMC: 11620538.
DOI: 10.1016/j.envint.2024.108930.
Alvarez D, Ortiz M, Valdebenito G, Crisosto N, Echiburu B, Valenzuela R
Nutrients. 2023; 15(21).
PMID: 37960348
PMC: 10649644.
DOI: 10.3390/nu15214696.
Younossi Z, Zelber-Sagi S, Henry L, Gerber L
Nat Rev Gastroenterol Hepatol. 2023; 20(11):708-722.
PMID: 37402873
DOI: 10.1038/s41575-023-00800-4.
Neri C, Scapaticci S, Chiarelli F, Giannini C
Int J Mol Sci. 2022; 23(9).
PMID: 35563210
PMC: 9100068.
DOI: 10.3390/ijms23094822.
Skeletal Muscle Mass Has Stronger Association With the Risk of Hyperuricemia Than Body Fat Mass in Obese Children and Adolescents.
Xie L, Mo P, Tang Q, Zhao X, Zhao X, Cai W
Front Nutr. 2022; 9:792234.
PMID: 35419385
PMC: 8995646.
DOI: 10.3389/fnut.2022.792234.
The adolescent with obesity: what perspectives for treatment?.
Nicolucci A, Maffeis C
Ital J Pediatr. 2022; 48(1):9.
PMID: 35033162
PMC: 8761267.
DOI: 10.1186/s13052-022-01205-w.
Decreased Sclerostin Secretion in Humans and Mice With Nonalcoholic Fatty Liver Disease.
Zhou F, Wang Y, Li Y, Tang M, Wan S, Tian H
Front Endocrinol (Lausanne). 2021; 12:707505.
PMID: 34421825
PMC: 8374147.
DOI: 10.3389/fendo.2021.707505.
Non-Alcoholic Fatty Liver Disease in Obese Youth With Insulin Resistance and Type 2 Diabetes.
Scapaticci S, DAdamo E, Mohn A, Chiarelli F, Giannini C
Front Endocrinol (Lausanne). 2021; 12:639548.
PMID: 33889132
PMC: 8056131.
DOI: 10.3389/fendo.2021.639548.
Comparative efficacy and safety of traditional Chinese patent medicine for NAFLD in childhood or adolescence: A protocol for a Bayesian network meta analysis.
Sun Y, Tan Z, Jiang Z, Li M, Wang W, Huang Y
Medicine (Baltimore). 2021; 100(3):e24277.
PMID: 33546051
PMC: 7837984.
DOI: 10.1097/MD.0000000000024277.
Angiopoietin-like 8 (ANGPTL8) as a potential predictor of NAFLD in paediatric patients with Prader-Willi Syndrome.
Mele C, Crino A, Fintini D, Mai S, Convertino A, Bocchini S
J Endocrinol Invest. 2020; 44(7):1447-1456.
PMID: 33067796
PMC: 8195791.
DOI: 10.1007/s40618-020-01444-w.
Bone marrow fat change in pediatric patients with non-alcoholic fatty liver disease.
Albakheet S, Yoon H, Shin H, Koh H, Kim S, Lee M
PLoS One. 2020; 15(6):e0234096.
PMID: 32484830
PMC: 7266329.
DOI: 10.1371/journal.pone.0234096.
Increased liver echogenicity and liver enzymes are associated with extreme obesity, adolescent age and male gender: analysis from the German/Austrian/Swiss obesity registry APV.
Greber-Platzer S, Thajer A, Bohn S, Brunert A, Boerner F, Siegfried W
BMC Pediatr. 2019; 19(1):332.
PMID: 31514755
PMC: 6739932.
DOI: 10.1186/s12887-019-1711-4.
The Liver in Children With Metabolic Syndrome.
DAdamo E, Castorani V, Nobili V
Front Endocrinol (Lausanne). 2019; 10:514.
PMID: 31428049
PMC: 6687849.
DOI: 10.3389/fendo.2019.00514.
The Level of Vitamin D in Children and Adolescents with Nonalcoholic Fatty Liver Disease: A Meta-Analysis.
Zhu S, Wang Y, Luo F, Liu J, Xiu L, Qin J
Biomed Res Int. 2019; 2019:7643542.
PMID: 31380438
PMC: 6662475.
DOI: 10.1155/2019/7643542.
Overview of Updated Practice Guidelines for Pediatric Nonalcoholic Fatty Liver Disease.
Shah J, Okubote T, Alkhouri N
Gastroenterol Hepatol (N Y). 2018; 14(7):407-414.
PMID: 30166956
PMC: 6111502.
The Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease.
Roychowdhury S, Selvakumar P, Cresci G
Med Sci (Basel). 2018; 6(2).
PMID: 29874807
PMC: 6024579.
DOI: 10.3390/medsci6020047.
Nonalcoholic Fatty Liver Disease in Children: Not a Small Matter.
Selvakumar P, Nasser Kabbany M, Alkhouri N
Paediatr Drugs. 2018; 20(4):315-329.
PMID: 29740791
DOI: 10.1007/s40272-018-0292-2.
Cardiovascular and Metabolic Complications - Diagnosis and Management in Obese Children.
Vikram N
Indian J Pediatr. 2017; 85(7):535-545.
PMID: 29218646
DOI: 10.1007/s12098-017-2504-0.